NasdaqGS - Delayed Quote USD
Taysha Gene Therapies, Inc. (TSHA)
2.7850
+0.0750
+(2.77%)
At close: June 2 at 4:00:00 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Cash Flow
-83,447
-81,225
-73,018
-88,390
-117,042
Investing Cash Flow
-594
-363
-7,352
-24,930
-21,554
Financing Cash Flow
76,654
76,684
136,393
52,097
39,083
End Cash Position
119,193
141,636
146,540
90,517
151,740
Interest Paid Supplemental Data
5,247
5,282
4,952
2,775
641
Capital Expenditure
-612
-374
-7,369
-24,869
-21,554
Issuance of Capital Stock
--
76,780
140,790
53,244
0
Issuance of Debt
--
0
39,550
0
39,957
Repayment of Debt
--
0
-43,000
0
0
Free Cash Flow
-84,059
-81,599
-80,387
-113,259
-138,596
12/31/2021 - 9/24/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ORIC ORIC Pharmaceuticals, Inc.
8.47
+3.67%
LXEO Lexeo Therapeutics, Inc.
2.7200
0.00%
TRVI Trevi Therapeutics, Inc.
6.32
-3.00%
ITOS iTeos Therapeutics, Inc.
10.01
-0.10%
MLTX MoonLake Immunotherapeutics
41.16
+5.51%
NGNE Neurogene Inc.
17.75
+4.35%
BCAX Bicara Therapeutics Inc.
9.90
+7.03%
SVRA Savara Inc.
2.4000
+5.26%
PRTA Prothena Corporation plc
4.6600
+1.53%
RCKT Rocket Pharmaceuticals, Inc.
2.7700
+10.36%